Immunology in Lung Cancer: Biomarker Relevance and Integration of Therapies for Maximum Clinical Benefit
 
Release Date: November 30, 2017
Last Reviewed: November 3, 2017
Expiration Date: November 30, 2018
Time to Complete Activity: 1.5 hours
 
Faculty
Naiyer A. Rizvi, MD (Chair)
Professor of Medicine
Director of Thoracic Oncology
Co-Director Cancer Immunotherapy Program
Columbia University Medical Center
New York, NY
 
David R. Gandara, MD
Professor, Director of Thoracic Oncology
Program, Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA
 
Heather A. Wakelee, MD
Associate Professor of Medicine
Department of Medicine
Division of Medical Oncology
Stanford University Medical Center
Stanford, CA

This activity is provided by Paradigm Medical Communications, LLC.  

Target Audience
This activity has been designed to address the educational needs of oncologists and multidisciplinary oncology care team practitioners. It will also be of benefit to other clinicians engaged with or interested in the treatment of lung cancer.
 
Learning Objectives
Upon proper completion of this activity, participants should be better able to:
  • Describe concepts of cancer immunology as they relate to the mechanisms of action of immune checkpoint inhibitors.
  • Evaluate the latest evidence regarding the clinical utility and limitations of biomarkers in guiding treatment decisions and evaluating immunotherapy response in lung cancer.
  • Apply the latest efficacy and response pattern data for immune checkpoint inhibitors to the treatment of various types of lung cancer.
  • Outline strategies for the effective multidisciplinary management of immune-related adverse effects associated with immune checkpoint inhibition in lung cancer, including identification, treatment, and patient education.
 
Table of Contents
Introduction and Exploiting Cancer Immunology
Integrating the Latest Efficacy Data into Clinical Practice
Collaborative Management of irAEs
Conclusions
 
 
 
 
 
 
Physician Accreditation Statement
Paradigm Medical Communications, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
Physician Credit Designation Statement
Paradigm Medical Communications, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Pharmacist Accreditation and Designation Statement
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.5 hours (0.15 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. (Universal Activity Number 0761-9999-17-325-H01-P)
 
This is a knowledge-based activity.
 
This activity is jointly provided by Educational Review Systems, Inc. and Paradigm Medical Communications, LLC.
                                                                                      
                                                                                      
PA Continuing Education
PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
 
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.  Individuals are responsible for checking with the AANPCP for further guidelines.
 
Disclosure of Commercial Support
This activity is supported by educational grants from Bristol-Myers Squibb, Genentech, Inc and Merck & Co., Inc.
 
Instructions for Participation
To receive CE credit, you should:
  • Follow instructions to register or log in with your professional information and complete the pre-activity assessment
  • View the online activity in its entirety.
  • Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest.
A certificate of participation/statement of completion will be available for download/printing immediately following your successful completion of the posttest and evaluation.

Please note: to claim CPE credit, please make sure you include your date of birth and NABP number. All credit information will be uploaded into CPE Monitor within 30 days.

For questions regarding CE credit, contact the Paradigm CME Department at (845) 398-5949.
 
There is no fee required for participation in this activity.

Hardware/Software Requirements
This certified CE activity is designed using HTML5 video, and audio. As you navigate the video using the supplied controls, the slides will sync to the speaker.
 
Supported Browsers:
For Desktops (Windows/Mac)
Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher
 
For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher
 
Technical Support: If you have any technical problems or playback issues email us at contactus@paradigmmc.com.
 
Disclosures
In accordance with ACCME and ACPE requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
 
Naiyer A. Rizvi, MD (Chair)
Retained Consultant: AstraZeneca; Bristol-Myers Squibb; Lilly; Merck & Co., Inc; Novartis; Roche; Pfizer Inc
Ownership: ARMO Biosciences; Gritstone Oncology
 
David R. Gandara, MD
Grant/Research Support: AstraZeneca/Medimmune; Genentech, Inc; Merck & Co., Inc
Retained Consultant: AstraZeneca/Medimmune; Genentech, Inc; Merck & Co., Inc
 
Heather A. Wakelee, MD
Grant/Research Support: AstraZeneca/Medimmune; Bristol-Myers Squibb; Celgene Corporation; Clovis Oncology; Exelixis, Inc; Genentech, Inc/Roche; Gilead; Lilly; Novartis; Pharmacyclics LLC; Xcovery
Retained Consultant: ACEA Biosciences, Inc; Genentech, Inc (uncompensated)

Paradigm Medical Communications, LLC, staff members have no financial relationships to disclose.

Educational Review Systems, Inc. staff members have no financial relationships to disclose.

Independent peer reviewer has no financial relationships to disclose.
 
Resolution of Conflict of Interest
Paradigm Medical Communications, LLC and Educational Review Systems, Inc. have implemented a system to resolve conflicts of interest for each CE activity to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public. Conflicts, if any, are resolved through one or more processes. All CE content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACPE Guidelines and ACCME’s Standards for Commercial Support of Continuing Medical Education.
 
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.
 
Disclaimer
This CE activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC or Educational Review Systems, Inc. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
 
As an ACCME-accredited provider, Paradigm Medical Communications, LLC, activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
 
Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the Faculty, and do not necessarily represent those of Paradigm Medical Communications, LLC or Educational Review Systems, Inc. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC or Educational Review Systems, Inc. Paradigm Medical Communications, LLC and Educational Review Systems, Inc accept no liability for the content referenced in this activity.
 
Privacy policy
Paradigm Medical Communications, LLC and Educational Review Systems, Inc. are committed to protecting the privacy of those who participate in the activities (herein referred to as “website") located at www.paradigmmc.com. The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
 
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
 
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CE activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC and Educational Review Systems, Inc. to continuously improve the learning experience.
 
Paradigm Medical Communications, LLC and Educational Review Systems, Inc do not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC and Educational Review Systems, Inc. will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC and Educational Review Systems, Inc. staff members review individual test results to the extent necessary to record and track participants’ credits.
 
Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com.
 
© 2017 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.